Ketamine in acute phase of severe traumatic brain injury "an old drug for new uses?"

Crit Care. 2021 Jan 6;25(1):19. doi: 10.1186/s13054-020-03452-x.

Abstract

Maintaining an adequate level of sedation and analgesia plays a key role in the management of traumatic brain injury (TBI). To date, it is unclear which drug or combination of drugs is most effective in achieving these goals. Ketamine is an agent with attractive pharmacological and pharmacokinetics characteristics. Current evidence shows that ketamine does not increase and may instead decrease intracranial pressure, and its safety profile makes it a reliable tool in the prehospital environment. In this point of view, we discuss different aspects of the use of ketamine in the acute phase of TBI, with its potential benefits and pitfalls.

Keywords: Agitation; Cooperative sedation; Ketamine; Neuroprotection; Secondary insult; Sedation; Traumatic brain injury.

MeSH terms

  • Anesthetics, Dissociative / pharmacology
  • Anesthetics, Dissociative / therapeutic use
  • Brain Injuries, Traumatic / drug therapy*
  • Brain Injuries, Traumatic / physiopathology
  • Humans
  • Hypnotics and Sedatives / pharmacology
  • Hypnotics and Sedatives / therapeutic use
  • Intracranial Pressure / drug effects
  • Ketamine / pharmacology*
  • Ketamine / therapeutic use
  • Time Factors*

Substances

  • Anesthetics, Dissociative
  • Hypnotics and Sedatives
  • Ketamine